Delving into the Latest Updates on LY-3050258 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Eli Lilly & Co.

Active Organization-

Inactive Organization

Eli Lilly & Co.

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

The main purpose of this study is to evaluate the safety and how well the body will handle a single dose of increasing strength of study drug LY3050258. Each participant will receive LY3050258 or placebo once, in each of 2 dosing periods. At least 7 days will pass between doses. This study will last approximately 45 days for each participant. Screening is required within 28 days before the start of the study.

Start Date01 Aug 2013

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with LY-3050258

Login to view more data

100 Translational Medicine associated with LY-3050258

Login to view more data

100 Patents (Medical) associated with LY-3050258

Login to view more data

100 Deals associated with LY-3050258

Login to view more data

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01929707 (CTgov)	Phase 1	-	38	LY3050258 (2 mg LY3050258 (Trunk))	xouwooyuby(iwfnvquhlg) = obbmgygdwe rmshafmoyh (pullfvbrrn, dxojzgixzu - bdcmcyhzgl) View more	-	23 Jul 2018
				LY3050258 (6 mg LY3050258 (Trunk))	xouwooyuby(iwfnvquhlg) = bahzmmkxlf rmshafmoyh (pullfvbrrn, jycehnwbof - dbbtysvhox) View more